Insys Therapeutics (INSY): Pipeline Progressing - RBC
- Top 10 News for 12/2: Crude Rips on OPEC Cut; Starbucks' Schultz Steps Down; Nonfarm Payrolls Flat in Nov.
- Unemployment Rate Drops to 4.6%
- Bond yields slip on U.S. jobs data, euro steady before Italy vote
- Alibaba (BABA) Founder Jack Ma Discuss Plans to Retire; 'I Don't Want to Die at the Office'
- Starbucks Coffee (SBUX) CEO Howard Schultz to Step Down, Appointed Executive Chairman; Kevin Johnson New CEO
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
RBC Capital analyst, Randall Stanicky, reiterated his Sector Perform rating on shares of INSYS Therapeutics (NASDAQ: INSY) and cut his price target to $23 (from $26) after the company reported an uneventful 3Q with the focus of the call heavily geared towards pipeline, where it sees a number of near-term catalysts.
The analyst revisited his estimates with a more conservative view on Subsys and pushed out Syndros into mid-2Q given uncertainty around launch timing. This delay in profit recognition, pressures the price target down to $23 but leaves the analyst with an Outperform rating.
Shares of INSYS Therapeutics closed at $10.02 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies Cuts Price Target on Workday (WDAY) to $71 Following 3Q
- Jefferies Cuts Price Target on Eros Int'l (EROS) to $18 Following Multi-Year Deal
- Jefferies Raises Price Target on Ulta Salon (ULTA) to $270; Reiterates Hold
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS Change, Analyst PT Change, Earnings
Related EntitiesRBC Capital
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!